Back to results
US 12,594,277 B2Granted
Macrocyclic ULK1/2 inhibitors
AssigneesThe Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute
InventorsNicholas D. P. Cosford, Nicole A. Bakas, Reuben J. Shaw, Allison S. Limpert, Sonja N. Brun
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ULK mediated diseases, including cancer.
Claims8
A compound or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof wherein the compound is selected from:
Dependencies are inferred from the claim text.